Search

Your search keyword '"Park, Joong‐Won"' showing total 721 results

Search Constraints

Start Over You searched for: Author "Park, Joong‐Won" Remove constraint Author: "Park, Joong‐Won"
721 results on '"Park, Joong‐Won"'

Search Results

1. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

3. Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

5. Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma

6. Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial.

8. Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study

9. Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW.

11. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial

12. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

13. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

14. APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy

15. Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction

19. Corrigendum to “EASL-ILCA clinical practice guidelines on the management of intrahepatic cholangiocarcinoma” [J Hepatol (79) (2023) 181–208]

20. Correction to: APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy

23. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma

24. Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images

25. Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers

26. Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context

27. Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas

28. Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types

29. Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas

30. Systematic Analysis of Splice-Site-Creating Mutations in Cancer

31. Driver Fusions and Their Implications in the Development and Treatment of Human Cancers

32. Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas

33. Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types

34. Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study

36. Sorafenib for 9,923 Patients with Hepatocellular Carcinoma: An Analysis from National Health Insurance Claim Data in South Korea

37. Feasibility of systemic anti-cancer therapy as an alternative to best supportive care in patients with advanced HCC and Child-Pugh B liver dysfunction

39. Transarterial Radioembolization versus Tyrosine Kinase Inhibitor in Hepatocellular Carcinoma with Portal Vein Thrombosis

42. EASL-ILCA Clinical Practice Guidelines on Intrahepatic Cholangiocarcinoma

43. Supplementary Data from First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma

44. Data from First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma

46. Supp Figure S3 from Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma

Catalog

Books, media, physical & digital resources